losartan has been researched along with Insulin Resistance in 78 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to observe the antihypertensive effect of losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension (EH) combined with isolated impaired fasting glucose (i-IFG)." | 9.22 | Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose. ( Jiang, XS; Liu, L; Ning, N; Tan, MH; Wei, P; Xiao, WY; Yi, D; Zhou, L, 2016) |
| "The aim of this study was to evaluate the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus." | 9.20 | Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. ( D'Angelo, A; Dario Ragonesi, P; Derosa, G; Franzetti, I; Maffioli, P; Querci, F, 2015) |
| "Inhibition of the rennin-angiotensin system (RAS) could reduce insulin resistance in patients with hypertension and diabetic kidney disease (DKD), but whether the effect of losartan on insulin resistance is associated with reduction of oxidative stress and enhancement of insulin signaling transduction has not been fully elucidated." | 9.20 | Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction. ( Fu, SK; Gu, HF; Hu, C; Jin, HM; Liu, XL; Pan, LH; Pan, Y; Qiao, QY; Zhou, DC, 2015) |
| " Since treatment with angiotensin II receptor blockers retards the development of diabetes, the effects of losartan on serum adiponectin levels were examined with regard to insulin sensitivity in pre-diabetic patients." | 9.13 | Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. ( Higuchi, C; Naito, T; Nishimura, H; Otsuka, K; Sanaka, T; Tanihata, Y, 2008) |
| "This study demonstrates that losartan significantly improved endothelial function in type 2 diabetes patients with hypertension compared with atenolol." | 9.12 | Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. ( Chenevard, R; Flammer, AJ; Gay, S; Hermann, F; Hürlimann, D; Lehmann, R; Lüscher, TF; Neidhart, M; Noll, G; Riesen, W; Ruschitzka, F; Schwegler, B; Sudano, I; Wiesli, P, 2007) |
| " To test telmisartan's clinical importance, we here investigated its effect on insulin resistance in hypertensive patients with metabolic syndrome (MetS) in comparison with another ARB, losartan." | 9.12 | Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. ( Bahadir, MA; Bahadir, O; Oguz, A; Uzunlulu, M, 2007) |
| "In addition to reducing urinary protein excretion, losartan at 100 mg daily increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetic nephropathy." | 9.12 | Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. ( Jin, HM; Pan, Y, 2007) |
| " We hypothesized that treatment with losartan as compared to atenolol would improve insulin sensitivity through regression of peripheral vascular hypertrophy/rarefaction." | 9.11 | Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. ( Andersen, UB; Fossum, E; Gaboury, CL; Hjerkinn, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Nesbitt, SD; Olsen, MH; Phillips, RA; Wachtell, K, 2005) |
| "The aim of this study was to compare the effects of trandolapril and losartan on plasminogen activator inhibitor type 1 (PAI-1) levels and insulin sensitivity in hypertensive postmenopausal women." | 9.09 | Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. ( Fogari, E; Fogari, R; Malamani, G; Mugellini, A; Preti, P; Zoppi, A, 2001) |
| " Therefore, we carried out a randomized, double-blind study to compare the effects of losartan (50 mg QD) and metoprolol (95 mg QD) on insulin sensitivity, insulin secretion, glucose tolerance, and lipids and lipoproteins in 20 hyperinsulinemic subjects with essential hypertension." | 9.08 | Effects of losartan on insulin sensitivity in hypertensive subjects. ( Karjalainen, L; Laakso, M; Lempiäinen-Kuosa, P, 1996) |
| "Twenty-five non diabetic subjects with mild to moderate hypertension, 11 females and 14 males, aged 44-63 years, after a 4-week wash-out period on placebo, were randomized to receive lisinopril 20 mg once daily or losartan 50 mg once daily for 6 weeks." | 9.08 | Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. ( Corradi, L; Fogari, R; Lazzari, P; Lusardi, P; Mugellini, A; Zoppi, A, 1998) |
| "The aim of this study was to compare the effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril and the angiotensin II antagonist losartan on insulin sensitivity and plasma fibrinogen in overweight hypertensive patients." | 9.08 | ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. ( Corradi, L; Fogari, R; Lazzari, P; Lusardi, P; Mugellini, A; Preti, P; Zoppi, A, 1998) |
| " Therefore the aim of this study was to investigate the effects of the angiotensin II-receptor antagonist losartan on insulin sensitivity, lipid profile, and plasma endothelin-1 (ET-1) levels in normotensive offspring of hypertensive parents with a randomized, double-blind, placebo- controlled, crossover design." | 9.08 | Effects of angiotensin II-receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents. ( Beissner, P; Lerch, M; Schneider, M; Shaw, SG; Teuscher, AU; Weidmann, P, 1998) |
| "We investigated the relationship between the homeostasis model assessment-insulin resistance index (HOMA-R) and various serum inflammatory markers and the effect of losartan on serum concentrations of these markers in patients with type 2 diabetes and hypertension." | 7.73 | Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension. ( Adachi, T; Fujinami, A; Fukui, M; Hara, H; Hasegawa, G; Kimura, F; Nakajima, Y; Nakamura, N; Obayashi, H; Ogata, M; Ohta, M; Park, H; Tamaki, S; Yoshikawa, T, 2006) |
| " However, the biological actions of angiotensin II (AII) on insulin sensitivity remain controversial." | 7.73 | Angiotensin II enhances insulin sensitivity in vitro and in vivo. ( Chang, CL; Chien, Y; Ho, LT; Ho, PH; Juan, CC; Kwok, CF; Lai, YH; Wu, LY; Yang, WM, 2005) |
| "These results suggest that reversal of high fructose-induced hypertension and insulin resistance by chronic losartan treatment is not dependent on AT2R activation and that functional activation of AT1R plays a major role in the pathogenesis of high fructose-induced hypertension and insulin resistance." | 7.73 | Reversal of fructose-induced hypertension and insulin resistance by chronic losartan treatment is independent of AT2 receptor activation in rats. ( Hsieh, PS, 2005) |
| "The specific inhibition of angiotensin II action at AT(1) receptors by losartan has been shown to decrease peripheral insulin resistance in type 2 diabetic patients and animal models." | 7.72 | Mechanism of improving effect of losartan on insulin sensitivity of non-insulin-dependent diabetes mellitus rats. ( Ouyang, JP; Wen, CY; Wu, K; Wu, Y; Zhao, DH; Zhou, YF, 2004) |
| "The purpose of this study was to evaluate the role of angiotensin II (AII) in fructose-treated rats by assessing the effects of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity." | 7.69 | Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats. ( Iyer, SN; Katovich, MJ, 1996) |
| "Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR." | 6.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "Insulin sensitivity was not improved." | 5.39 | Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats. ( Chang, CF; Chao, YW; Chen, JY; Huang, SW; Jian, DY; Juan, CC; Ting, CH, 2013) |
| "Treatment with losartan in the NIDDM rats caused a significant decrease in insulin levels and reduction in elevated fasting and fed glucose levels." | 5.31 | Improvement in insulin sensitivity by losartan in non-insulin-dependent diabetic (NIDDM) rats. ( Goyal, RK; Murali, B, 2001) |
| "Hypertension often complicates type 2 diabetes mellitus, and angiotensin converting enzyme inhibitor treatment has been shown to improve insulin resistance in such cases." | 5.31 | Effects of losartan in combination with or without exercise on insulin resistance in Otsuka Long-Evans Tokushima Fatty rats. ( Ebina, Y; Houchi, H; Ishizawa, K; Kishi, K; Minakuchi, K; Nakaya, Y; Takishita, E; Tamaki, T; Tsuchiya, K; Yoshizumi, M, 2001) |
| "Pretreatment with losartan (40 mg/kg/d) did not improve insulin action in the SHR." | 5.30 | Insulin resistance in adipocytes from spontaneously hypertensive rats: effect of long-term treatment with enalapril and losartan. ( Caldiz, CI; de Cingolani, GE, 1999) |
| "The objective of this study was to observe the antihypertensive effect of losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension (EH) combined with isolated impaired fasting glucose (i-IFG)." | 5.22 | Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose. ( Jiang, XS; Liu, L; Ning, N; Tan, MH; Wei, P; Xiao, WY; Yi, D; Zhou, L, 2016) |
| "The aim of this study was to evaluate the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus." | 5.20 | Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. ( D'Angelo, A; Dario Ragonesi, P; Derosa, G; Franzetti, I; Maffioli, P; Querci, F, 2015) |
| "Inhibition of the rennin-angiotensin system (RAS) could reduce insulin resistance in patients with hypertension and diabetic kidney disease (DKD), but whether the effect of losartan on insulin resistance is associated with reduction of oxidative stress and enhancement of insulin signaling transduction has not been fully elucidated." | 5.20 | Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction. ( Fu, SK; Gu, HF; Hu, C; Jin, HM; Liu, XL; Pan, LH; Pan, Y; Qiao, QY; Zhou, DC, 2015) |
| " The aim of this study was to evaluate the effects of losartan or amlodipine alone or combined with simvastatin on hepatic steatosis degree, and on insulin sensitivity in normocholesterolemic, hypertensive patients with nonalcoholic hepatic steatosis." | 5.16 | Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A, 2012) |
| " Since treatment with angiotensin II receptor blockers retards the development of diabetes, the effects of losartan on serum adiponectin levels were examined with regard to insulin sensitivity in pre-diabetic patients." | 5.13 | Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. ( Higuchi, C; Naito, T; Nishimura, H; Otsuka, K; Sanaka, T; Tanihata, Y, 2008) |
| " STAR-LET was a 6-month extension of the Study of Trandolapril/Verapamil SR and Insulin Resistance (STAR), which assessed the effects of a fixed-dose renin-angiotensin system inhibitor (RASI)/hydrochlorothiazide (HCTZ) combination on changes in 2-hour oral glucose tolerance test (OGTT) results." | 5.13 | Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. ( Bacher, P; Bakris, G; Champion, A; Molitch, M; Sarafidis, P; Sowers, JR; Zhou, Q, 2008) |
| "In addition to reducing urinary protein excretion, losartan at 100 mg daily increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetic nephropathy." | 5.12 | Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. ( Jin, HM; Pan, Y, 2007) |
| "This study demonstrates that losartan significantly improved endothelial function in type 2 diabetes patients with hypertension compared with atenolol." | 5.12 | Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. ( Chenevard, R; Flammer, AJ; Gay, S; Hermann, F; Hürlimann, D; Lehmann, R; Lüscher, TF; Neidhart, M; Noll, G; Riesen, W; Ruschitzka, F; Schwegler, B; Sudano, I; Wiesli, P, 2007) |
| " To test telmisartan's clinical importance, we here investigated its effect on insulin resistance in hypertensive patients with metabolic syndrome (MetS) in comparison with another ARB, losartan." | 5.12 | Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. ( Bahadir, MA; Bahadir, O; Oguz, A; Uzunlulu, M, 2007) |
| "Losartan raised serum levels of free IGF-I, which might contribute to the improvement of insulin resistance associated with losartan treatment." | 5.12 | Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I. ( Bootsma, AH; Janssen, JA; Lamberts, SW; Zandbergen, AA, 2006) |
| " We hypothesized that treatment with losartan as compared to atenolol would improve insulin sensitivity through regression of peripheral vascular hypertrophy/rarefaction." | 5.11 | Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. ( Andersen, UB; Fossum, E; Gaboury, CL; Hjerkinn, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Nesbitt, SD; Olsen, MH; Phillips, RA; Wachtell, K, 2005) |
| " Calculated insulin sensitivity index also improved in the enalapril-treated group (p=0." | 5.10 | Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. ( Akalin, S; Akpinar, I; Deyneli, O; Haklar, G; Koç, M; Toprak, A; Velioğlu, A; Yavuz, D, 2003) |
| "The aim of this study was to compare the effects of trandolapril and losartan on plasminogen activator inhibitor type 1 (PAI-1) levels and insulin sensitivity in hypertensive postmenopausal women." | 5.09 | Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. ( Fogari, E; Fogari, R; Malamani, G; Mugellini, A; Preti, P; Zoppi, A, 2001) |
| " Therefore, we carried out a randomized, double-blind study to compare the effects of losartan (50 mg QD) and metoprolol (95 mg QD) on insulin sensitivity, insulin secretion, glucose tolerance, and lipids and lipoproteins in 20 hyperinsulinemic subjects with essential hypertension." | 5.08 | Effects of losartan on insulin sensitivity in hypertensive subjects. ( Karjalainen, L; Laakso, M; Lempiäinen-Kuosa, P, 1996) |
| " Therefore the aim of this study was to investigate the effects of the angiotensin II-receptor antagonist losartan on insulin sensitivity, lipid profile, and plasma endothelin-1 (ET-1) levels in normotensive offspring of hypertensive parents with a randomized, double-blind, placebo- controlled, crossover design." | 5.08 | Effects of angiotensin II-receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents. ( Beissner, P; Lerch, M; Schneider, M; Shaw, SG; Teuscher, AU; Weidmann, P, 1998) |
| "The aim of this study was to compare the effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril and the angiotensin II antagonist losartan on insulin sensitivity and plasma fibrinogen in overweight hypertensive patients." | 5.08 | ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. ( Corradi, L; Fogari, R; Lazzari, P; Lusardi, P; Mugellini, A; Preti, P; Zoppi, A, 1998) |
| "Twenty-five non diabetic subjects with mild to moderate hypertension, 11 females and 14 males, aged 44-63 years, after a 4-week wash-out period on placebo, were randomized to receive lisinopril 20 mg once daily or losartan 50 mg once daily for 6 weeks." | 5.08 | Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. ( Corradi, L; Fogari, R; Lazzari, P; Lusardi, P; Mugellini, A; Zoppi, A, 1998) |
| " We treated patients who had NASH and hypertension with losartan, an angiotensin II receptor antagonist for 48 weeks." | 4.83 | [Clinical utility of angiotensin II receptor antagonist]. ( Haneda, M; Nakamura, K; Yokohama, S, 2006) |
| "Male C57BL/6 J mice with high fat-high sucrose diet (HF-HSD) induced NASH, obesity, insulin resistance and hypercholesterolemia were subjected to dietary intervention (switch from HF-HSD to normal chow diet (NCD)) (n = 9), continuation HF-HSD together with losartan (30 mg/kg/day) (n = 9) or continuation HF-HSD only (n = 9) for 8 weeks." | 3.85 | Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice. ( Bedossa, P; Cammue, B; Cassiman, D; Nevens, F; Spincemaille, P; Thevissen, K; Van den Berghe, G; van der Merwe, S; van Pelt, J; Vander Elst, I; Vanhorebeek, I; Verbeek, J; Windmolders, P, 2017) |
| "The high-fat diet elicited overweight, insulin resistance and adipocyte hypertrophy in the high-fat group, all of which losartan rescued in the high-fat-losartan group." | 3.85 | AT1 receptor antagonist induces thermogenic beige adipocytes in the inguinal white adipose tissue of obese mice. ( Barbosa-da-Silva, S; de Oliveira Santos, F; Graus-Nunes, F; Rachid, TL; Souza-Mello, V, 2017) |
| "Glucose metabolism, insulin, lipid, and ACE activity disorders observed with obesity were minimized by Losartan." | 3.80 | AT1 receptor blockade attenuates insulin resistance and myocardial remodeling in rats with diet-induced obesity. ( Campos, DH; Cicogna, AC; Fernandes, T; Guizoni, DM; Martinez, PF; Okoshi, K; Okoshi, MP; Oliveira, EM; Oliveira-Junior, SA; Padovani, CR, 2014) |
| " In other rats, glucose, insulin, uric acid, and insulin sensitivity index, were determined before and after fructose or lipoic acid plus fructose." | 3.79 | A single oral dose of fructose induces some features of metabolic syndrome in rats: role of oxidative stress. ( Hong, E; Moreno, JA, 2013) |
| " In addition to measuring BW, circulating glucose level, and BP, the following procedures were also carried out: insulin challenge (insulin sensitivity), losartan challenge (renin-angiotensin system activity), Nw-nitro-L arginine-methyl ester hydrochloride (LNAME) challenge (nitric oxide [NO] system activity), and evaluation of serum angiotensin converting enzyme (ACE) activity." | 3.78 | Fraction SX of maitake mushroom favorably influences blood glucose levels and blood pressure in streptozotocin-induced diabetic rats. ( Bagchi, D; Echard, B; Fu, J; Kaylor, M; Perricone, NV; Preuss, HG; Zhuang, C, 2012) |
| " Blocking the actions of Angiotensin II with an AT1 receptor antagonist (Losartan), has beneficial effects in patients with insulin resistance or type 2 diabetes mellitus." | 3.77 | ANG II type I receptor antagonism improved nitric oxide production and enhanced eNOS and PKB/Akt expression in hearts from a rat model of insulin resistance. ( Friedrich, SO; Huisamen, B; Lochner, A; Pêrel, SJ; Salie, R; Strijdom, H, 2011) |
| " We hypothesized that insulin-induced relaxation and the associated proline-rich tyrosine kinase 2 (Pyk2)/Src/Akt pathway would be abnormal in aortas from the Goto-Kakizaki (GK) type 2 diabetic rat, which exhibits hyperglycemia/insulin resistance, and that losartan treatment of such rats (25 mg·kg(-1)·day(-1) for 2 wk) would correct these abnormalities." | 3.77 | Losartan improves aortic endothelium-dependent relaxation via proline-rich tyrosine kinase 2/Src/Akt pathway in type 2 diabetic Goto-Kakizaki rats. ( Kamata, K; Kobayashi, T; Matsumoto, T; Nemoto, S; Taguchi, K, 2011) |
| "These results suggest that reversal of high fructose-induced hypertension and insulin resistance by chronic losartan treatment is not dependent on AT2R activation and that functional activation of AT1R plays a major role in the pathogenesis of high fructose-induced hypertension and insulin resistance." | 3.73 | Reversal of fructose-induced hypertension and insulin resistance by chronic losartan treatment is independent of AT2 receptor activation in rats. ( Hsieh, PS, 2005) |
| "We investigated the relationship between the homeostasis model assessment-insulin resistance index (HOMA-R) and various serum inflammatory markers and the effect of losartan on serum concentrations of these markers in patients with type 2 diabetes and hypertension." | 3.73 | Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension. ( Adachi, T; Fujinami, A; Fukui, M; Hara, H; Hasegawa, G; Kimura, F; Nakajima, Y; Nakamura, N; Obayashi, H; Ogata, M; Ohta, M; Park, H; Tamaki, S; Yoshikawa, T, 2006) |
| " However, the biological actions of angiotensin II (AII) on insulin sensitivity remain controversial." | 3.73 | Angiotensin II enhances insulin sensitivity in vitro and in vivo. ( Chang, CL; Chien, Y; Ho, LT; Ho, PH; Juan, CC; Kwok, CF; Lai, YH; Wu, LY; Yang, WM, 2005) |
| " We examined the possibility that an angiotensin II type 1 (AT1) receptor blocker, losartan, enhances insulin sensitivity and thereby increases glucose tolerance in thermally injured rats." | 3.73 | Blockade of the renin-angiotensin system improves insulin sensitivity in thermal injury. ( Castle, SM; Daley, BJ; Enderson, BL; Karlstad, MD; Kasper, SO, 2006) |
| "ACE inhibitors (ACEIs) improve insulin resistance and prevent type 2 diabetes, possibly mediated by inhibition of bradykinin (BK) degradation." | 3.72 | Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I recept ( Giacca, A; Lapointe, N; Leung, N; Lewis, GF; Rouleau, JL; Szeto, L; Uffelman, KD; Wang, CH, 2003) |
| "The specific inhibition of angiotensin II action at AT(1) receptors by losartan has been shown to decrease peripheral insulin resistance in type 2 diabetic patients and animal models." | 3.72 | Mechanism of improving effect of losartan on insulin sensitivity of non-insulin-dependent diabetes mellitus rats. ( Ouyang, JP; Wen, CY; Wu, K; Wu, Y; Zhao, DH; Zhou, YF, 2004) |
| " Accordingly, ingestion of chromium and antioxidants which improve insulin sensitivity and/or lessen free radical formation could theoretically ameliorate these basic disorders and lessen signs and symptoms of chronic age-related disorders." | 3.71 | Long-term effects of chromium, grape seed extract, and zinc on various metabolic parameters of rats. ( Bagchi, D; Echard, B; Montamarry, S; Preuss, HG; Scheckenbach, R, 2001) |
| " To further explore the mechanisms underlying fructose-induced hypertension, the effects of the AT1 receptor antagonist losartan on blood pressure, insulin resistance, renal function, and vascular reactivity in mesenteric vascular beds were studied." | 3.69 | Effects of losartan on blood pressure, metabolic alterations, and vascular reactivity in the fructose-induced hypertensive rat. ( Cachofeiro, V; Lahera, V; Maeso, R; Navarro-Cid, J; Perez-Vizcaino, F; Ruilope, LM; Tamargo, J, 1995) |
| "The objective of this study was to investigate the effect of Losartan (NK-954, DuP-753), a new selective angiotensin II receptor antagonist, on insulin sensitivity and sympathetic nervous system activity in patients with severe primary hypertension." | 3.69 | The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. ( Eide, I; Kjeldsen, SE; Moan, A; Risanger, T, 1994) |
| "The purpose of this study was to evaluate the role of angiotensin II (AII) in fructose-treated rats by assessing the effects of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity." | 3.69 | Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats. ( Iyer, SN; Katovich, MJ, 1996) |
| "Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR." | 2.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "Simvastatin combined with losartan improves endothelial function and reduces inflammatory markers to a greater extent than monotherapy with either drug in hypercholesterolemic, hypertensive patients." | 2.71 | Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. ( Ahn, JY; Ahn, TH; Choi, IS; Chung, WJ; Han, SH; Kang, MH; Koh, KK; Quon, MJ; Seo, YH; Shin, EK, 2004) |
| "Proteinuria is a sign of established kidney damage and plays a direct pathogenic role in the progression of renal and cardiovascular disease." | 2.43 | Time to abandon microalbuminuria? ( Remuzzi, G; Ruggenenti, P, 2006) |
| "The potential benefit for treatment of the metabolic syndrome, cardiovascular protection, and prevention of related end-organ complications could be of immense clinical value." | 2.43 | Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. ( Pershadsingh, HA, 2006) |
| "Losartan treatment alleviated some of the T2DM- induced metabolic complications, abolished the T2DM-induced hypo activity, and normalized the corticosterone level, carbonylated proteins in brain, nociception and memory." | 1.56 | Protective effects of losartan on some type 2 diabetes mellitus-induced complications in Wistar and spontaneously hypertensive rats. ( Grozdanov, P; Kostadinova, N; Krumova, E; Mitreva-Staleva, J; Pechlivanova, D; Stoynev, A, 2020) |
| "We studied the effect of apelin treatment on obesity-induced type 2 diabetes mellitus (T2DM) and possible interaction between apelin/APJ system and renin-angiotensin system (RAS)." | 1.51 | Interactive effects of apelin, renin-angiotensin system and nitric oxide in treatment of obesity-induced type 2 diabetes mellitus in male albino rats. ( Ahmed, MM; Kamar, SS; Mahmoud, MM; Rashed, L; Sabry, MM; Shoukry, HS, 2019) |
| "Enalapril was the most successful treatment in protecting against hepatic IR and NAFLD by enhancing hepatic insulin action, leptin, and gluconeogenesis and by reducing the lipogenic pathway and lipid accumulation in the liver." | 1.40 | Comparative effects of the renin-angiotensin system blockers on nonalcoholic fatty liver disease and insulin resistance in C57BL/6 mice. ( Aguila, MB; Batista, Tde M; Frantz, ED; Mandarim-de-Lacerda, CA; Penna-de-Carvalho, A, 2014) |
| "Insulin sensitivity was not improved." | 1.39 | Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats. ( Chang, CF; Chao, YW; Chen, JY; Huang, SW; Jian, DY; Juan, CC; Ting, CH, 2013) |
| "Obesity is often associated with chronic inflammatory state which contributes to the development of insulin resistance (IR) and type 2 diabetes mellitus (T2DM)." | 1.39 | Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats. ( El-Moselhy, MA; Heeba, GH; Mourad, AA; Taye, A, 2013) |
| "Losartan treatment could be an effective tool to restore normal vascular reactivity in the renal circulation of the fructose-fed rat." | 1.38 | The effect of losartan and carvedilol on renal haemodynamics and altered metabolism in fructose-fed Sprague-Dawley rats. ( Abdulla, MH; Abdullah, NA; Johns, EJ; Sattar, MA, 2012) |
| "Captopril treatment partially reversed low insulin sensitivity in LSD rats, whereas losartan did not change it, which indicates that the effect of LSD on insulin sensitivity is angiotensin independent." | 1.31 | High- or low-salt diet from weaning to adulthood: effect on insulin sensitivity in Wistar rats. ( Dolnikoff, MS; Furukawa, LN; Heimann, JC; Machado, UF; Okamoto, MM; Prada, P, 2000) |
| "Hypertension often complicates type 2 diabetes mellitus, and angiotensin converting enzyme inhibitor treatment has been shown to improve insulin resistance in such cases." | 1.31 | Effects of losartan in combination with or without exercise on insulin resistance in Otsuka Long-Evans Tokushima Fatty rats. ( Ebina, Y; Houchi, H; Ishizawa, K; Kishi, K; Minakuchi, K; Nakaya, Y; Takishita, E; Tamaki, T; Tsuchiya, K; Yoshizumi, M, 2001) |
| "Treatment with losartan in the NIDDM rats caused a significant decrease in insulin levels and reduction in elevated fasting and fed glucose levels." | 1.31 | Improvement in insulin sensitivity by losartan in non-insulin-dependent diabetic (NIDDM) rats. ( Goyal, RK; Murali, B, 2001) |
| "Pretreatment with losartan (40 mg/kg/d) did not improve insulin action in the SHR." | 1.30 | Insulin resistance in adipocytes from spontaneously hypertensive rats: effect of long-term treatment with enalapril and losartan. ( Caldiz, CI; de Cingolani, GE, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (12.82) | 18.2507 |
| 2000's | 39 (50.00) | 29.6817 |
| 2010's | 27 (34.62) | 24.3611 |
| 2020's | 2 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Pechlivanova, D | 1 |
| Krumova, E | 1 |
| Kostadinova, N | 1 |
| Mitreva-Staleva, J | 1 |
| Grozdanov, P | 1 |
| Stoynev, A | 1 |
| Walke, PB | 1 |
| Bansode, SB | 1 |
| More, NP | 1 |
| Chaurasiya, AH | 1 |
| Joshi, RS | 1 |
| Kulkarni, MJ | 1 |
| Sabry, MM | 1 |
| Mahmoud, MM | 1 |
| Shoukry, HS | 1 |
| Rashed, L | 1 |
| Kamar, SS | 1 |
| Ahmed, MM | 1 |
| Jian, DY | 1 |
| Chao, YW | 1 |
| Ting, CH | 1 |
| Huang, SW | 1 |
| Chang, CF | 1 |
| Juan, CC | 2 |
| Chen, JY | 1 |
| Sagae, SC | 1 |
| Lubaczeuski, C | 1 |
| Zacharias, P | 1 |
| Bonfleur, ML | 1 |
| Franci, CR | 1 |
| Sanvitto, GL | 1 |
| Oliveira-Junior, SA | 1 |
| Martinez, PF | 1 |
| Guizoni, DM | 1 |
| Campos, DH | 1 |
| Fernandes, T | 1 |
| Oliveira, EM | 1 |
| Okoshi, MP | 1 |
| Okoshi, K | 1 |
| Padovani, CR | 1 |
| Cicogna, AC | 1 |
| Frantz, ED | 1 |
| Penna-de-Carvalho, A | 1 |
| Batista, Tde M | 1 |
| Aguila, MB | 1 |
| Mandarim-de-Lacerda, CA | 1 |
| Pan, Y | 3 |
| Qiao, QY | 1 |
| Pan, LH | 1 |
| Zhou, DC | 1 |
| Hu, C | 2 |
| Gu, HF | 1 |
| Fu, SK | 1 |
| Liu, XL | 1 |
| Jin, HM | 3 |
| Derosa, G | 2 |
| Querci, F | 1 |
| Franzetti, I | 1 |
| Dario Ragonesi, P | 1 |
| D'Angelo, A | 1 |
| Maffioli, P | 2 |
| Sun, F | 1 |
| Song, Y | 1 |
| Liu, J | 1 |
| Ma, LJ | 1 |
| Shen, Y | 1 |
| Huang, J | 1 |
| Zhou, YL | 1 |
| Cicero, AF | 1 |
| Tocci, G | 1 |
| Xiao, WY | 1 |
| Ning, N | 1 |
| Tan, MH | 1 |
| Jiang, XS | 1 |
| Zhou, L | 1 |
| Liu, L | 1 |
| Yi, D | 1 |
| Wei, P | 1 |
| Muñoz, MC | 1 |
| Burghi, V | 1 |
| Miquet, JG | 1 |
| Cervino, IA | 1 |
| Quiroga, DT | 1 |
| Mazziotta, L | 1 |
| Dominici, FP | 1 |
| Tian, X | 1 |
| Ye, M | 1 |
| Cao, Y | 1 |
| Wang, C | 1 |
| Graus-Nunes, F | 1 |
| Rachid, TL | 1 |
| de Oliveira Santos, F | 1 |
| Barbosa-da-Silva, S | 1 |
| Souza-Mello, V | 1 |
| Verbeek, J | 1 |
| Spincemaille, P | 1 |
| Vanhorebeek, I | 1 |
| Van den Berghe, G | 1 |
| Vander Elst, I | 1 |
| Windmolders, P | 1 |
| van Pelt, J | 1 |
| van der Merwe, S | 1 |
| Bedossa, P | 1 |
| Nevens, F | 1 |
| Cammue, B | 1 |
| Thevissen, K | 1 |
| Cassiman, D | 1 |
| Singh, B | 1 |
| Mourya, A | 1 |
| Sah, SP | 1 |
| Kumar, A | 1 |
| Aksnes, TA | 3 |
| Flaa, A | 1 |
| Sevre, K | 1 |
| Mundal, HH | 1 |
| Rostrup, M | 1 |
| Kjeldsen, SE | 6 |
| Nishimura, H | 1 |
| Sanaka, T | 1 |
| Tanihata, Y | 1 |
| Naito, T | 1 |
| Higuchi, C | 1 |
| Otsuka, K | 1 |
| Georgescu, EF | 1 |
| Guo, LL | 1 |
| Ogino, K | 1 |
| Kato, M | 1 |
| Furuse, Y | 1 |
| Kinugasa, Y | 1 |
| Kaetsu, Y | 1 |
| Mizuta, E | 1 |
| Sugihara, S | 1 |
| Ishida, K | 1 |
| Yanagihara, K | 1 |
| Hisatome, I | 1 |
| Shigemasa, C | 1 |
| Huisamen, B | 1 |
| Pêrel, SJ | 1 |
| Friedrich, SO | 1 |
| Salie, R | 1 |
| Strijdom, H | 1 |
| Lochner, A | 1 |
| Guo, Q | 1 |
| Mori, T | 1 |
| Jiang, Y | 1 |
| Ohsaki, Y | 1 |
| Yoneki, Y | 1 |
| Nakamichi, T | 1 |
| Ogawa, S | 1 |
| Sato, H | 1 |
| Ito, S | 1 |
| Nemoto, S | 1 |
| Kobayashi, T | 1 |
| Taguchi, K | 1 |
| Matsumoto, T | 1 |
| Kamata, K | 1 |
| Prior, SJ | 1 |
| Lteif, AA | 1 |
| Chisholm, RL | 1 |
| Gilbert, K | 1 |
| Considine, RV | 1 |
| Mather, KJ | 1 |
| Fogari, R | 4 |
| Mugellini, A | 4 |
| Zoppi, A | 4 |
| Lazzari, P | 3 |
| Garcia-Touza, M | 1 |
| Sowers, JR | 2 |
| Abdulla, MH | 1 |
| Sattar, MA | 1 |
| Abdullah, NA | 1 |
| Johns, EJ | 1 |
| Moreno, JA | 1 |
| Hong, E | 1 |
| Mourad, AA | 1 |
| Heeba, GH | 1 |
| Taye, A | 1 |
| El-Moselhy, MA | 1 |
| Preuss, HG | 2 |
| Echard, B | 2 |
| Fu, J | 1 |
| Perricone, NV | 1 |
| Bagchi, D | 2 |
| Kaylor, M | 1 |
| Zhuang, C | 1 |
| Brown, NJ | 1 |
| Kumar, S | 1 |
| Painter, CA | 1 |
| Vaughan, DE | 1 |
| Wang, CH | 1 |
| Leung, N | 1 |
| Lapointe, N | 1 |
| Szeto, L | 1 |
| Uffelman, KD | 1 |
| Giacca, A | 1 |
| Rouleau, JL | 1 |
| Lewis, GF | 1 |
| Krizanova, O | 1 |
| Sebokova, E | 1 |
| Klimes, I | 1 |
| Yavuz, D | 1 |
| Koç, M | 1 |
| Toprak, A | 1 |
| Akpinar, I | 1 |
| Velioğlu, A | 1 |
| Deyneli, O | 1 |
| Haklar, G | 1 |
| Akalin, S | 1 |
| Shinozaki, K | 1 |
| Ayajiki, K | 1 |
| Nishio, Y | 1 |
| Sugaya, T | 1 |
| Kashiwagi, A | 1 |
| Okamura, T | 1 |
| Nielsen, S | 1 |
| Lihn, AS | 1 |
| ØStergaard, T | 1 |
| Mogensen, CE | 1 |
| Schmitz, O | 1 |
| Schupp, M | 1 |
| Janke, J | 1 |
| Clasen, R | 1 |
| Unger, T | 1 |
| Kintscher, U | 1 |
| Okigaki, M | 1 |
| Iwasaka, T | 1 |
| Wu, Y | 1 |
| Ouyang, JP | 1 |
| Zhou, YF | 1 |
| Wu, K | 1 |
| Zhao, DH | 1 |
| Wen, CY | 1 |
| Koh, KK | 1 |
| Quon, MJ | 1 |
| Han, SH | 1 |
| Chung, WJ | 1 |
| Ahn, JY | 1 |
| Seo, YH | 1 |
| Kang, MH | 1 |
| Ahn, TH | 1 |
| Choi, IS | 1 |
| Shin, EK | 1 |
| Chien, Y | 1 |
| Wu, LY | 1 |
| Yang, WM | 1 |
| Chang, CL | 1 |
| Lai, YH | 1 |
| Ho, PH | 1 |
| Kwok, CF | 1 |
| Ho, LT | 1 |
| Olsen, MH | 1 |
| Fossum, E | 1 |
| Høieggen, A | 2 |
| Wachtell, K | 1 |
| Hjerkinn, E | 1 |
| Nesbitt, SD | 1 |
| Andersen, UB | 1 |
| Phillips, RA | 1 |
| Gaboury, CL | 1 |
| Ibsen, H | 1 |
| Julius, S | 1 |
| Yoshida, D | 1 |
| Higashiura, K | 1 |
| Shimamoto, K | 1 |
| Hsieh, PS | 1 |
| Pershadsingh, HA | 1 |
| Yokohama, S | 1 |
| Nakamura, K | 1 |
| Haneda, M | 1 |
| Park, H | 1 |
| Hasegawa, G | 1 |
| Obayashi, H | 1 |
| Fujinami, A | 1 |
| Ohta, M | 1 |
| Hara, H | 1 |
| Adachi, T | 1 |
| Tamaki, S | 1 |
| Nakajima, Y | 1 |
| Kimura, F | 1 |
| Ogata, M | 1 |
| Fukui, M | 1 |
| Yoshikawa, T | 1 |
| Nakamura, N | 1 |
| Zandbergen, AA | 1 |
| Lamberts, SW | 1 |
| Janssen, JA | 1 |
| Bootsma, AH | 1 |
| Ruggenenti, P | 1 |
| Remuzzi, G | 1 |
| Yoshizumi, M | 2 |
| Ishizawa, K | 2 |
| Izawa, Y | 1 |
| Tamaki, T | 2 |
| Reims, HM | 1 |
| Guptha, S | 1 |
| Moan, A | 4 |
| Os, I | 1 |
| Kasper, SO | 1 |
| Castle, SM | 1 |
| Daley, BJ | 1 |
| Enderson, BL | 1 |
| Karlstad, MD | 1 |
| Flammer, AJ | 1 |
| Hermann, F | 1 |
| Wiesli, P | 1 |
| Schwegler, B | 1 |
| Chenevard, R | 1 |
| Hürlimann, D | 1 |
| Sudano, I | 1 |
| Gay, S | 1 |
| Neidhart, M | 1 |
| Riesen, W | 1 |
| Ruschitzka, F | 1 |
| Lüscher, TF | 1 |
| Noll, G | 1 |
| Lehmann, R | 1 |
| Bahadir, O | 1 |
| Uzunlulu, M | 1 |
| Oguz, A | 1 |
| Bahadir, MA | 1 |
| Seljeflot, I | 1 |
| Torjesen, PA | 1 |
| Höieggen, A | 1 |
| Bakris, G | 1 |
| Molitch, M | 1 |
| Zhou, Q | 1 |
| Sarafidis, P | 1 |
| Champion, A | 1 |
| Bacher, P | 1 |
| Navarro-Cid, J | 1 |
| Maeso, R | 1 |
| Perez-Vizcaino, F | 1 |
| Cachofeiro, V | 1 |
| Ruilope, LM | 1 |
| Tamargo, J | 1 |
| Lahera, V | 1 |
| Risanger, T | 1 |
| Eide, I | 1 |
| Nordby, G | 1 |
| Eide, IK | 1 |
| Laakso, M | 1 |
| Karjalainen, L | 1 |
| Lempiäinen-Kuosa, P | 1 |
| Iyer, SN | 1 |
| Katovich, MJ | 1 |
| Paolisso, G | 1 |
| Tagliamonte, MR | 1 |
| Gambardella, A | 1 |
| Manzella, D | 1 |
| Gualdiero, P | 1 |
| Varricchio, G | 1 |
| Verza, M | 1 |
| Varricchio, M | 1 |
| Lerch, M | 1 |
| Teuscher, AU | 1 |
| Beissner, P | 1 |
| Schneider, M | 1 |
| Shaw, SG | 1 |
| Weidmann, P | 1 |
| Preti, P | 2 |
| Corradi, L | 2 |
| Lusardi, P | 2 |
| Caldiz, CI | 1 |
| de Cingolani, GE | 1 |
| Prada, P | 1 |
| Okamoto, MM | 1 |
| Furukawa, LN | 1 |
| Machado, UF | 1 |
| Heimann, JC | 1 |
| Dolnikoff, MS | 1 |
| Feldman, R | 1 |
| Fogari, E | 1 |
| Malamani, G | 1 |
| Montamarry, S | 1 |
| Scheckenbach, R | 1 |
| Tsuchiya, K | 1 |
| Takishita, E | 1 |
| Nakaya, Y | 1 |
| Kishi, K | 1 |
| Ebina, Y | 1 |
| Houchi, H | 1 |
| Minakuchi, K | 1 |
| Murali, B | 1 |
| Goyal, RK | 1 |
| Fishman, S | 1 |
| Rapoport, MJ | 1 |
| Weissgarten, J | 1 |
| Zaidenstein, R | 1 |
| Dishi, V | 1 |
| Hartzeanu, I | 1 |
| Golik, A | 1 |
| Khan, MA | 1 |
| Morgan, RJ | 1 |
| Mikhailidis, DP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adiponectin is Positively Associated With Insulin Resistance in Subjects With Type 2 Diabetic Nephropathy and Effects by Angiotensin Type 1 Receptor Blocker Losartan[NCT00774904] | 80 participants (Actual) | Interventional | 2007-04-30 | Completed | |||
| Losartan Improved Insulin Resistance and Decreased Inflammatory Cytokines in Patients With Chronic Heart Failure Treated With Angiotensin Converting Enzyme Inhibitors[NCT00663377] | Phase 4 | 16 participants (Anticipated) | Interventional | 2006-04-30 | Completed | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Glucose Optimisation With Angiotensin II Antagonist Losartan in Patients With Hypertension and Other Risk Factors for Metabolic Syndrome (GOAAL)[NCT00237588] | Phase 4 | 25 participants | Interventional | 2004-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
9 reviews available for losartan and Insulin Resistance
| Article | Year |
|---|---|
Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Fat | 2008 |
Evidence-based hypertension treatment in patients with diabetes.
Topics: Albuminuria; Antihypertensive Agents; Diabetic Angiopathies; Diabetic Nephropathies; Endothelium, Va | 2012 |
[Involvement of angiotensin II in pathogenesis of hypertension and target organ damage].
Topics: Angioplasty, Balloon, Coronary; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin | 2004 |
[Treatment of hypertensive patients with impaired glucose tolerance (IGT)].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Tri | 2006 |
[Clinical utility of angiotensin II receptor antagonist].
Topics: Angiotensin II Type 1 Receptor Blockers; Fatty Liver; Humans; Hypertension; Insulin Resistance; Live | 2006 |
Time to abandon microalbuminuria?
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers; | 2006 |
[Intracellular signal transduction of vascular injury in insulin resistance].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; | 2006 |
ACE inhibitors versus AT1 blockers in the treatment of hypertension and syndrome X.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2000 |
27 trials available for losartan and Insulin Resistance
| Article | Year |
|---|---|
Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction.
Topics: 3T3-L1 Cells; Adipocytes; Aged; Amlodipine; Animals; Antihypertensive Agents; Diabetic Nephropathies | 2015 |
Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus.
Topics: Adipokines; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2015 |
Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Essential Hypertension; F | 2016 |
Effects on plasma noradrenaline may explain some of the improved insulin sensitivity seen by AT-1 receptor blockade.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cross-Over Studies; Doubl | 2008 |
Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism.
Topics: Adiponectin; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Fe | 2008 |
Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.
Topics: Adiponectin; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabe | 2009 |
Addition of losartan to angiotensin-converting enzyme inhibitors improves insulin resistance in patients with chronic heart failure treated without β-blockers.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2010 |
Effects of losartan on whole body, skeletal muscle and vascular insulin responses in obesity/insulin resistance without hypertension.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Dose-Response Relationship, Drug; Dou | 2012 |
Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2012 |
ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2002 |
Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2003 |
Increased plasma adiponectin in losartan-treated type 1 diabetic patients. a mediator of improved insulin sensitivity?
Topics: Adiponectin; Adult; Angiotensin Receptor Antagonists; Blood Glucose; Cross-Over Studies; Diabetes Me | 2004 |
Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; C-Reactive Protein | 2004 |
Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; F | 2005 |
Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; F | 2006 |
Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Bloo | 2006 |
Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; C-Peptide; Calcium | 2007 |
Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Brachial Artery; Cross-Over Studies; Diabetes Mel | 2007 |
Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Glucose; Bloo | 2007 |
Improved insulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity.
Topics: Adipokines; Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Cross-Over Studies; Double-Bl | 2007 |
Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study.
Topics: Analysis of Variance; Chi-Square Distribution; Diabetes Mellitus; Diuretics; Female; Glucose Toleran | 2008 |
Effects of losartan on insulin sensitivity in hypertensive subjects.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Fatty Acids, Nones | 1996 |
Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients.
Topics: Antihypertensive Agents; Biphenyl Compounds; Female; Glucose; Hemodynamics; Humans; Hypertension; Im | 1997 |
Effects of angiotensin II-receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cholesterol, HDL; Cross-Over Studi | 1998 |
ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients.
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cross-Over | 1998 |
Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Blood Press | 1998 |
Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Bl | 2001 |
42 other studies available for losartan and Insulin Resistance
| Article | Year |
|---|---|
Protective effects of losartan on some type 2 diabetes mellitus-induced complications in Wistar and spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Brain; Corticosterone; Diabetes Mellitus, Experime | 2020 |
Molecular investigation of glycated insulin-induced insulin resistance via insulin signaling and AGE-RAGE axis.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Glucose; Glucose Transporter Type 4; Glycation End Produ | 2021 |
Interactive effects of apelin, renin-angiotensin system and nitric oxide in treatment of obesity-induced type 2 diabetes mellitus in male albino rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apelin; Biomarkers; Blood Glucose; Diabetes Mellit | 2019 |
Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats.
Topics: Adipokines; Adiposity; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Ce | 2013 |
Prevention of metabolic disorders and reproductive performance deficits by the blockade of Angiotensin II AT1 receptor in female rats fed with cafeteria diet.
Topics: Adipose Tissue; Angiotensin Receptor Antagonists; Animals; Body Weight; Cholesterol; Diet, High-Fat; | 2013 |
AT1 receptor blockade attenuates insulin resistance and myocardial remodeling in rats with diet-induced obesity.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Blood Glucose; Class Ia Phosphatidyl | 2014 |
Comparative effects of the renin-angiotensin system blockers on nonalcoholic fatty liver disease and insulin resistance in C57BL/6 mice.
Topics: Adipose Tissue; Amides; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Enalapril; | 2014 |
Efficacy of losartan for improving insulin resistance and vascular remodeling in hemodialysis patients.
Topics: Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Carotid Arteries; Female; Humans; In | 2016 |
Metabolic approaches to antihypertensive treatment in diabetic patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Calcium | 2015 |
Chronic blockade of the AT2 receptor with PD123319 impairs insulin signaling in C57BL/6 mice.
Topics: Adiponectin; Adipose Tissue; Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Animals; Chemo | 2017 |
Losartan Improves Palmitate-Induced Insulin Resistance in 3T3-L1 Adipocytes Through Upregulation of Src Phosphorylation.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Insulin Resistance; Losartan; Mice; Palmitic Acid; Phosphorylatio | 2017 |
AT1 receptor antagonist induces thermogenic beige adipocytes in the inguinal white adipose tissue of obese mice.
Topics: Adipocytes, Beige; Adipose Tissue, White; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Gl | 2017 |
Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; CD36 Antigens; Collagen Type I, alpha 1 Chain; Dru | 2017 |
Protective effect of losartan and ramipril against stress induced insulin resistance and related complications: Anti-inflammatory mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Biomarkers; Insulin Resistance; Losartan; Male; Mice; Ramipril; R | 2017 |
ANG II type I receptor antagonism improved nitric oxide production and enhanced eNOS and PKB/Akt expression in hearts from a rat model of insulin resistance.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiac Output; Diet; In Vitro Techniques; Insulin | 2011 |
Losartan modulates muscular capillary density and reverses thiazide diuretic-exacerbated insulin resistance in fructose-fed rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Capillaries; Fructose; Glucose Clamp Technique; Hy | 2012 |
Losartan improves aortic endothelium-dependent relaxation via proline-rich tyrosine kinase 2/Src/Akt pathway in type 2 diabetic Goto-Kakizaki rats.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Angiotensin II; Angiotensin II Type 1 Receptor Blocker | 2011 |
Anti-hypertensive therapy and insulin sensitivity: regulation through the microcirculation?
Topics: Animals; Capillaries; Fructose; Hydrochlorothiazide; Insulin Resistance; Losartan; Male; Muscle, Ske | 2012 |
The effect of losartan and carvedilol on renal haemodynamics and altered metabolism in fructose-fed Sprague-Dawley rats.
Topics: Angiotensin II; Animals; Body Weight; Carbazoles; Carvedilol; Fructose; Glucose Tolerance Test; Hemo | 2012 |
A single oral dose of fructose induces some features of metabolic syndrome in rats: role of oxidative stress.
Topics: Administration, Oral; Animals; Blood Glucose; Blood Pressure; Dose-Response Relationship, Drug; Fruc | 2013 |
Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, | 2013 |
Fraction SX of maitake mushroom favorably influences blood glucose levels and blood pressure in streptozotocin-induced diabetic rats.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Grifola; Hypog | 2012 |
Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I recept
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biological Tran | 2003 |
Effect of losartan on the Na+/Ca2+ exchanger in left ventricle of the insulin resistant and hypertensive hHTg rat.
Topics: Animals; Biological Transport, Active; Gene Expression Regulation; Heart Ventricles; Hypertension; H | 2002 |
Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blood Pressure; Calcimycin; | 2004 |
Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.
Topics: 3T3 Cells; Acrylates; Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; | 2004 |
Mechanism of improving effect of losartan on insulin sensitivity of non-insulin-dependent diabetes mellitus rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose Transporter Type 4; Ins | 2004 |
Angiotensin II enhances insulin sensitivity in vitro and in vivo.
Topics: Adipocytes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Drug Sy | 2005 |
Reversal of fructose-induced hypertension and insulin resistance by chronic losartan treatment is independent of AT2 receptor activation in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Antihyper | 2005 |
Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension.
Topics: Anti-Inflammatory Agents; Biomarkers; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Infla | 2006 |
Blockade of the renin-angiotensin system improves insulin sensitivity in thermal injury.
Topics: Angiotensin II; Animals; Area Under Curve; Blood Glucose; Burns; Insulin; Insulin Resistance; Losart | 2006 |
Effects of losartan on blood pressure, metabolic alterations, and vascular reactivity in the fructose-induced hypertensive rat.
Topics: Analysis of Variance; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Gl | 1995 |
The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Glucose; Blood Pressure; Fe | 1994 |
Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity?
Topics: Adult; Analysis of Variance; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Blood Gluc | 1995 |
Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1996 |
Insulin resistance in adipocytes from spontaneously hypertensive rats: effect of long-term treatment with enalapril and losartan.
Topics: Adipocytes; Animals; Antihypertensive Agents; Biological Transport; Enalapril; Glucose; Hypertension | 1999 |
High- or low-salt diet from weaning to adulthood: effect on insulin sensitivity in Wistar rats.
Topics: Aging; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biological Transp | 2000 |
Long-term effects of chromium, grape seed extract, and zinc on various metabolic parameters of rats.
Topics: Aging; Animals; Antihypertensive Agents; Blood Chemical Analysis; Blood Pressure; Body Weight; Chrom | 2001 |
Effects of losartan in combination with or without exercise on insulin resistance in Otsuka Long-Evans Tokushima Fatty rats.
Topics: Adipocytes; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Blotting, Western; Body | 2001 |
Improvement in insulin sensitivity by losartan in non-insulin-dependent diabetic (NIDDM) rats.
Topics: Animals; Antihypertensive Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insuli | 2001 |
The effect of Losartan on insulin resistance and beta cell function in chronic hemodialysis patients.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure Determination; Female; | 2001 |
The choice of antihypertensive drugs in patients with erectile dysfunction.
Topics: Aged; Antihypertensive Agents; Diabetes Complications; Doxazosin; Erectile Dysfunction; Humans; Hype | 2002 |